AB InBev Reports Q2 Earnings Growth

InflaRx N.V. is set to announce its Q2 2024 financial results on August 8, highlighting its advancements in anti-inflammatory therapeutics, particularly its lead candidate vilobelimab, an anti-C5a monoclonal antibody. Meanwhile, beer giant AB InBev reported a 10.2% rise in normalized EBITDA for Q2 2024, surpassing analyst forecasts, despite a 0.8% decline in total sales volumes, largely due to poor performance in China and Argentina. The company's revenues increased by 2.7%, driven by strong growth in megabrands like Corona, while underlying EPS rose by 25% compared to the previous year. CEO Michel Doukeris expressed optimism about the company's performance, attributing growth to strategic cost management and revenue optimization initiatives. AB InBev is facing challenges from ongoing inflation and shifts in consumer demand, particularly following the boycott of Bud Light, which has affected its market share in the U.S. but shows signs of recovery. Analysts remain cautiously optimistic about the company's potential to exceed full-year forecasts, despite the mixed performance across different regions.